Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy

HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Proc Natl Acad Sci U S A
Hlavní autoři: Floros, Konstantinos V., Lochmann, Timothy L., Hu, Bin, Monterrubio, Carles, Hughes, Mark T., Wells, Jason D., Morales, Cristina Bernadó, Ghotra, Maninderjit S., Costa, Carlotta, Souers, Andrew J., Boikos, Sosipatros A., Leverson, Joel D., Tan, Ming, Serra, Violeta, Koblinski, Jennifer E., Arribas, Joaquin, Prat, Aleix, Paré, Laia, Miller, Todd W., Dozmorov, Mikhail G., Harada, Hisashi, Windle, Brad E., Scaltriti, Maurizio, Faber, Anthony C.
Médium: Artigo
Jazyk:Inglês
Vydáno: National Academy of Sciences 2018
Témata:
PNAS Plus
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856537/
https://ncbi.nlm.nih.gov/pubmed/29476008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1717820115
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky